Joseph J. Ferra's Insider Trades & SAST Disclosures
Joseph J. Ferra's most recent trade in Elevation Oncology Inc was a trade of 6,250 Common Stock done . Disclosure was reported to the exchange on May 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Joseph J. Ferra.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 6,250 | 139,455 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 6,250 | 68,750 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.30 per share. | 15 May 2025 | 2,303 | 137,152 | - | 0.3 | 690 | Common Stock |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 12,562 | 12,560 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 12,562 | 137,833 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.53 per share. | 16 Mar 2025 | 4,628 | 133,205 | - | 0.5 | 2,466 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2025 | 7,884 | 15,768 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2025 | 7,884 | 284,219 (0%) | 0% | 0 | Common Stock | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.49 per share. | 13 Mar 2025 | 3,861 | 280,358 (0%) | 0% | 55.5 | 214,247 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 60,430 | 60,430 | - | - | Performance Based Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 28,438 | 28,438 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2025 | 24,898 | 286,517 (0%) | 0% | 0 | Common Stock | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2025 | 15,020 | 0 | - | - | Performance Based Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.49 per share. | 09 Mar 2025 | 10,182 | 276,335 (0%) | 0% | 74.5 | 758,457 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2025 | 4,451 | 0 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2025 | 4,150 | 4,150 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2025 | 1,277 | 1,888 | - | - | Dividend Equivalent Units | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 800,000 | 800,000 | - | - | Stock Option (Right to Buy) | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 25,000 | 134,482 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 25,000 | 75,000 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 15 Feb 2025 | 9,211 | 125,271 | - | 0.7 | 6,187 | Common Stock |
| Elevation Oncology Inc | J. Ferra Joseph | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 12,563 | 114,111 | - | - | Common Stock | |
| Elevation Oncology Inc | J. Joseph Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 12,563 | 25,122 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | J. Ferra Joseph | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.64 per share. | 16 Dec 2024 | 4,629 | 109,482 | - | 0.6 | 2,963 | Common Stock |
| Catalent Inc. | Joseph A. Ferraro | SVP, General Counsel, CCO | Sale of securities on an exchange or to another person at price $ 59.97 per share. | 18 Oct 2024 | 320 | 23,967 (0%) | 0% | 60.0 | 19,190 | Common Stock |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 12,562 | 37,685 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 12,562 | 106,176 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.61 per share. | 16 Sep 2024 | 4,628 | 101,548 | - | 0.6 | 2,823 | Common Stock |
| Catalent Inc. | Joseph A. Ferraro | SVP, General Counsel, CCO | Sale of securities on an exchange or to another person at price $ 59.58 per share. | 02 Aug 2024 | 608 | 24,287 (0%) | 0% | 59.6 | 36,225 | Common Stock |
| Catalent Inc. | Joseph A. Ferraro | SVP, General Counsel, CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2024 | 17,042 | 24,895 (0%) | 0% | 0 | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 12,562 | 50,247 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 12,562 | 98,242 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.23 per share. | 16 Jun 2024 | 4,628 | 93,614 | - | 3.2 | 14,948 | Common Stock |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 12,562 | 62,809 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 12,562 | 90,453 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.39 per share. | 16 Mar 2024 | 4,773 | 85,680 | - | 4.4 | 20,953 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 23,652 | 23,652 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 23,652 | 23,652 | - | - | Performance Based Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 86,651 | 304,056 (0%) | 0% | 0 | Common Stock | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 60,222 | 0 | - | - | Performance Based Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 111.96 per share. | 09 Mar 2024 | 42,437 | 261,619 (0%) | 0% | 112.0 | 4,751,247 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 13,383 | 0 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 4,450 | 4,451 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 4,446 | 3,075 | - | - | Dividend Equivalent Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 4,150 | 8,300 | - | - | Restricted Stock Units | |
| Elevation Oncology Inc | Joseph Ferra J. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 100,000 | 100,000 | - | - | Restricted Stock Unit | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2023 | 6,435 | 6,435 | - | - | Dividend Equivalent Units | |
| Elevation Oncology Inc | J. Joseph Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2023 | 12,563 | 82,664 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2023 | 12,563 | 75,371 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | J. Joseph Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.51 per share. | 16 Dec 2023 | 4,773 | 77,891 | - | 0.5 | 2,434 | Common Stock |
| Avis Budget Group Inc | A. Ferraro Joseph | President and CEO | Sale of securities on an exchange or to another person at price $ 195.30 per share. | 15 Dec 2023 | 7,630 | 224,212 (0%) | 0% | 195.3 | 1,490,139 | Common Stock |
| Avis Budget Group Inc | A. Joseph Ferraro | President and CEO | Sale of securities on an exchange or to another person at price $ 196.17 per share. | 15 Dec 2023 | 6,807 | 217,405 (0%) | 0% | 196.2 | 1,335,329 | Common Stock |
| Avis Budget Group Inc | A. Ferraro Joseph | President and CEO | Sale of securities on an exchange or to another person at price $ 194.33 per share. | 15 Dec 2023 | 4,023 | 231,842 (0%) | 0% | 194.3 | 781,790 | Common Stock |
| Catalent Inc. | Ferraro A. Joseph | SVP, General Counsel, CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Oct 2023 | 5,902 | 5,902 | - | - | Options to purchase Common Stock | |
| Catalent Inc. | Joseph A. Ferraro | SVP, General Counsel, CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Oct 2023 | 2,708 | 7,853 (0%) | 0% | 0 | Common Stock | |
| Catalent Inc. | Ferraro Joseph A. | SVP, General Counsel, CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2023 | 11,459 | 11,459 | - | - | Options to purchase Common Stock | |
| Catalent Inc. | Joseph Ferraro A. | SVP, General Counsel, CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2023 | 5,145 | 5,145 (0%) | 0% | 0 | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Elevation Oncology Inc | Joseph J. Ferra | INTERIM CEO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 12,563 | 100,496 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | INTERIM CEO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 12,563 | 67,085 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | INTERIM CEO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.47 per share. | 16 Jun 2023 | 4,773 | 62,312 | - | 1.5 | 7,016 | Common Stock |
| Elevation Oncology Inc | Joseph J. Ferra | INTERIM CEO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 12,563 | 113,059 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | INTERIM CEO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 12,563 | 59,295 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | INTERIM CEO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.35 per share. | 16 Mar 2023 | 4,773 | 54,522 | - | 2.4 | 11,217 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 128,471 | 298,780 (0%) | 0% | 0 | Common Stock | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 94,832 | 0 | - | - | Performance Based Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 208.84 per share. | 09 Mar 2023 | 62,915 | 235,865 (0%) | 0% | 208.8 | 13,139,169 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 15,806 | 0 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 13,383 | 13,383 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 12,450 | 12,450 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 12,450 | 12,450 | - | - | Performance Based Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 4,450 | 8,901 | - | - | Restricted Stock Units | |
| Elevation Oncology Inc | Joseph J. Ferra | INTERIM CEO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 270,000 | 270,000 | - | - | Stock Option (Right to Buy) | |
| Elevation Oncology Inc | Joseph J. Ferra | INTERIM CEO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Elevation Oncology Inc | Joseph J. Ferra | INTERIM CEO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 18,300 | 18,300 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Sale of securities on an exchange or to another person at price $ 185.40 per share. | 15 Dec 2022 | 13,300 | 170,409 (0%) | 0% | 185.4 | 2,465,820 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Sale of securities on an exchange or to another person at price $ 182.30 per share. | 15 Dec 2022 | 1,700 | 184,609 (0%) | 0% | 182.3 | 309,910 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Sale of securities on an exchange or to another person at price $ 183.32 per share. | 15 Dec 2022 | 900 | 183,709 (0%) | 0% | 183.3 | 164,988 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Sale of securities on an exchange or to another person at price $ 186.06 per share. | 15 Dec 2022 | 100 | 170,309 (0%) | 0% | 186.1 | 18,606 | Common Stock |
| Elevation Oncology Inc | Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 50,249 | 150,746 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 50,249 | 50,249 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 16 Jun 2022 | 19,095 | 31,154 | - | 1.3 | 24,060 | Common Stock |
| Elevation Oncology Inc | Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 12,562 | 125,622 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 12,562 | 51,505 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 12,562 | 138,184 | - | - | Restricted Stock Unit | |
| Elevation Oncology Inc | Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 12,562 | 43,716 | - | - | Common Stock | |
| Elevation Oncology Inc | Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.95 per share. | 16 Jun 2022 | 4,773 | 46,732 | - | 0.9 | 4,534 | Common Stock |
| Elevation Oncology Inc | Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.25 per share. | 16 Jun 2022 | 4,773 | 38,943 | - | 1.2 | 5,966 | Common Stock |
| Innovate Corp | Joseph A. Ferraro | Chief Legal Officer & Corp Sec | Sale of securities on an exchange or to another person at price $ 3.57 per share. | 16 Mar 2022 | 8,626 | 343,306 (0%) | 0% | 3.6 | 30,811 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 50,258 | 210,922 (0%) | 0% | 0 | Common Stock | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 43,078 | 0 | - | - | Performance Based Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 231.63 per share. | 15 Mar 2022 | 24,613 | 186,309 (0%) | 0% | 231.6 | 5,701,109 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 7,180 | 0 | - | - | Restricted Stock Units | |
| Innovate Corp | Joseph A. Ferraro | Chief Legal Officer & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 64,304 | 351,932 (0%) | 0% | 0 | Common Stock | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 29,187 | 174,958 (0%) | 0% | 0 | Common Stock | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 15,805 | 15,806 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 194.74 per share. | 09 Mar 2022 | 14,294 | 160,664 (0%) | 0% | 194.7 | 2,783,614 | Common Stock |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 13,382 | 26,766 | - | - | Restricted Stock Units | |
| Avis Budget Group Inc | Joseph A. Ferraro | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 13,351 | 13,351 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges